REGENXBIO Announces Presentations at the American Society of Gene and Cell Therapy's 23rd Annual Meeting
The oral presentations include:
Abstract Title: Quantitative PET/CT based pharmacokinetic study of AAV9 administered to the cerebrospinal fluid of non-human primates (abstract #135)
Session Title: AAV Vectors Preclinical and Proof-of-Concept Studies in Optimizing the Toolbox
Presenter: Mikhail Papisov, Ph.D.,
Date/Time: Tuesday, May 12, 2020 from
Abstract Title: RGX-314 Ocular Gene Therapy: Overview of Phase I/IIa Ongoing Trial for Neovascular Age-related Macular Degeneration (nAMD) and Future Directions (abstract #1305)
Session Title: AAV Vectors - Clinical Studies
Presenter:
Date/Time:
Abstract Title: AAV gene therapy in mucopolysaccharidosis IVA murine models (abstract #1351)
Session Title: Gene Therapy for Inborn Errors of Metabolism: New Approaches
Presenter:
Date/Time: Friday, May 15, 2020 from
The posters include:
Abstract Title: AAV-mediated antibody delivery for hereditary angioedema (abstract #190)
Presenter:
Session Title: AAV Vectors - Preclinical and Proof-of-Concept Studies
Date/Time: Tuesday, May 12, 2020 from
Abstract Title: Interim data from the first in human RGX-121 gene therapy trial for the treatment of severe MPS II (Hunter syndrome) (abstract #614)
Presenter:
Session Title: AAV Vectors - Clinical Studies
Date/Time: Wednesday, May 13, 2020 from
Abstract Title: Development of a vectorized antibody platform for liver and skeletal muscle gene transfer (abstract #556)
Presenter:
Session Title: AAV Vectors – Virology & Vectorology
Date/Time: Wednesday, May 13, 2020 from
Abstract Title: Use of Prophylactic Steroids to Mitigate Potential T-Cell Response in AAV8-Mediated hLDLR Gene Transfer in Subjects with Homozygous Familial Hypercholesterolemia (abstract #612)
Presenter:
Session Title: AAV Vectors - Clinical Studies
Date/Time: Wednesday, May 13, 2020 from
Abstract Title: Process development and scaleup comparisons for transient Production of AAV (abstract #1266)
Presenter:
Session Title: Vector and Cell Engineering, Production or Manufacturing
Date/Time: Thursday, May 14, 2020 from
Abstract Title: Structural and biochemical characterization of potentially under-utilized gene therapy vector AAV7 (abstract #1007)
Presenter:
Session Title: AAV Vectors - Virology and Vectorology
Date/Time: Thursday, May 14, 2020 from
Abstract Title: Development of a Sensitive and Robust Cell-Based Assay for Measuring Potency of the NAV AAV8 Vector-Derived RGX-314 Gene Therapy Product for the Treatment of Wet Age-Related Macular Degeneration (abstract #1005)
Presenter:
Session Title: AAV Vectors - Virology and Vectorology
Date/Time: Thursday, May 14, 2020 from
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.
Contacts:
Investor Relations and Corporate Communications
347-926-7709
ttruehart@regenxbio.com
Investors:
heather@argotpartners.com
Media:
david.rosen@argotpartners.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/regenxbio-announces-presentations-at-the-american-society-of-gene-and-cell-therapys-23rd-annual-meeting-301048853.html
SOURCE